Savara’s $100 Million Common Stock Offering

Laura Testa North America Legal Chronicle
Tagged:

Holland & Knight advised Savara on the offering.Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced a $100 million underwritten…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Laura Testa

Author: Laura Testa

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here